RE:Keytruda resistance shown as a monotherapy in anal cancerThis study demonstrates that immune checkpoint inhibitors are relatively ineffective as a monotherapy and require combination with ONCY's oncolytic virus pelareorep to affect a favorable tumor microenvironment (TME) for the addition of checkpoint inhibitors and the enhancement of CD8 + PD-(L)1 + T cells for an effective anti-tumor response.
https://jitc.bmj.com/content/12/1/e008436?rss=1